Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Crossref DOI link: https://doi.org/10.1186/s13075-016-0985-2
Published Online: 2016-04-14
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mueller, Ruediger B.
Gengenbacher, Michael
Richter, Symi
Dudler, Jean
Möller, Burkhard
von Kempis, Johannes
Funding for this research was provided by:
Bristol-Myers-Squibb, Princeton, NJ, USA